FLUOZEROC trial (FLUOrescence as a tracker for a ZERO CC0 Cyto-reduction for Colo-rectal peritoneal metastases)

Abstract

Background: The rate of recurrence after cytoreductive surgery (CRS) and Hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastasis of colorectal origin remains high despite important advances in multimodal treatment. Previous studies have demonstrated that there is remaining disease in the normal-looking peritoneum after a complete CRS and HIPEC in up to 30% of the patients. Fluorescence-guided (FG) surgery is revolutionizing oncologic surgery as it can signal in real time primary or metastatic lesions thanks to indocyanine green (ICG) or targeted dyes as EMI-137, a specific dye for colorectal cancer cells.